Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021
The Pharma Data
MARCH 17, 2021
percent compared to ET alone – a statistically significant improvement in invasive disease-free survival for HR+, HER2- high risk early breast cancer (HR: 0.713; 95% CI: 0.583, 0.871; p = 0.0009). Tolaney, MD, MPH, Harvard Medical School, Dana-Farber Cancer Institute. Overall, patient compliance for PROs was greater than 90 percent.
52 
Let's personalize your content